TGFB1 and neoplasm: In this work, we address the hurdles hampering the immune responses toward the poorly immunogenic tumor by combining a cRGD‐linked polymer‐lipid hybrid nanoparticle co‐delivering LTX‐315 peptide and TGF‐β1 siRNA (LTX/siR‐NPs) with an NKG2A inhibitor (Scheme 1, Figure 1a).